Studies involving hundreds of thousands of women have consistently shown that the ThinPrep® Pap Test increases detection of precancerous cells over the conventional Pap smear.

The ThinPrep Pap Test is the most widely used method for cervical cancer screening in the United States. It was developed to address the limitations of the conventional Pap smear, and after rigorous clinical trials, it was approved in May 1996 by the U.S. Food and Drug Administration (FDA) as a replacement for the conventional Pap smear. The ThinPrep Pap Test is the only liquid-based cytology method approved by the FDA as "significantly more effective" than the conventional Pap smear for detection of cervical abnormalities.

Most importantly, since FDA approval, more than 170 studies have been published, in peer-reviewed medical journals, demonstrating a wide range of clinical benefits of the ThinPrep Pap Test including increased disease detection, reduction of equivocal diagnoses, improved specimen adequacy, cost effectiveness and the ability to perform additional tests out of the same vial, such as human papillomavirus (HPV), Chlamydia and Gonorrhea (CT/NG). The ThinPrep Pap Test is currently the only liquid-based cytology method approved by the FDA for HPV, CT/NG testing and improved detection of glandular lesions.